Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly and Amylin end diabetes relationship; Amylin gets back exenatide rights

Executive Summary

Amylin Pharmaceuticals Inc. (metabolic disease therapies) and Eli Lilly & Co. are ending a close to ten-year relationship that was focused on the development and commercialization of diabetes drugs. Amylin is regaining worldwide rights to the cornerstone of the partnership--exenatide.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Reverse Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register